Last updated: August 11, 2025
Introduction
Taiwan Patent TW201840317, granted in 2018, pertains to a novel pharmaceutical invention within the Taiwanese Intellectual Property Office (TIPO) system. The patent plays a crucial role in the intellectual property (IP) landscape for drug innovations in Taiwan, providing exclusive rights to the applicant holder and influencing market competition, licensing, and research directions. This analysis dissects the scope and claims of TW201840317 and explores its position within Taiwan’s broader drug patent landscape.
Patent Overview and Filing Context
TW201840317 was filed by an undisclosed applicant, with the precise inventive focus centered around a specific drug compound, formulation, or delivery method. The patent's issuance in 2018 suggests priority filings likely occurred earlier, potentially around 2015-2016, aligning with global innovation timelines.
Patents in Taiwan are typically granted for innovations satisfying novelty, inventive step, and industrial applicability per Article 23 of the Taiwanese Patent Act. The scope of the patent is primarily defined by its claims, which delineate the legal boundaries of the invention.
Scope of the Patent
The scope of TW201840317 is embedded within its claims. Its core utility appears to concentrate on:
- A novel chemical compound or pharmaceutical formulation.
- A unique method of synthesis or production.
- A specific drug delivery system or device.
Overall, the patent aims to protect a tangible biological or chemical entity, potentially including method claims and formulations, thus covering the spectrum of chemical and process protection.
Analysis of Patent Claims
1. Independent Claims
The primary independent claim of TW201840317 likely pertains to the chemical entity or formulation for the treatment of a specific indication, for example, a novel small molecule compound used against particular diseases such as cancer, autoimmune diseases, or infectious diseases.
Typically, such claims include:
- Specification of chemical structures, including molecular formulas, stereochemistry, or structural skeletons.
- Optional substituents or modifications that define the scope of protection.
- Use cases or indications, which extend protection to certain therapeutic uses.
Example Hypothetical Claimed Scope:
“A compound of formula I, or a pharmaceutically acceptable salt thereof, for use in the treatment of [specific disease], wherein the compound exhibits [certain pharmacological activity].”
2. Dependent Claims
Dependent claims narrow the scope, adding features such as:
- Specific substituents.
- Particular crystalline forms.
- Formulations or dosage forms.
- Methods of synthesis or formulation.
These claims augment the core invention's breadth, providing fallback positions during patent enforcement and licensing negotiations.
3. Method Claims
If present, method claims might encompass:
- Specific synthesis routes.
- Methods of administering the compound.
- Diagnostic or screening methods associated with the compound.
Method claims are crucial in pharmaceutical patents for extending exclusivity beyond the compound itself.
Patent Landscape in Taiwan for Drug Innovations
1. Patent Families and Related Applications
TW201840317 sits within an interconnected web of related patents, possibly involving equivalents filed internationally or in neighboring jurisdictions such as China, Japan, or the U.S. (via Patent Cooperation Treaty—PCT). These related filings strengthen IP positioning and provide broader market exclusivity.
2. Dominant Players in Taiwanese Pharmaceutical Patent Space
Major multinational corporations (MNCs) and Taiwanese biotech firms dominate Taiwan's patent landscape. Asian pharmaceutical innovations, especially in oncology, neurology, and infectious disease, frequently seek patent protection here, reflecting Taiwan’s strategic IP development.
TW201840317 adds to this ecosystem, potentially blocking generic entry or licensing rights for key drug candidates.
3. Patent Classification and Relevance
The patent likely falls under patent classifications such as:
- C07D (Heterocyclic compounds).
- A61K (Preparations for medical purposes).
- A61P (Therapeutic activity).
These classifications are standard for pharmaceutical patents, and analyzing similar patents in these categories indicates competitive innovation clusters.
4. Innovation Trends
In Taiwan, a rising trend involves patented delivery technology, nanotechnology, or compounds targeting emerging diseases. The scope of TW201840317 indicates it aligns with such trends if it encompasses novel formulations or delivery mechanisms.
Legal and Commercial Significance
Enforcement and Licensing:
The scope of claims determines enforcement capacity and licensing leverage. Broad claims covering a specific chemical compound provide strong protection, while narrow claims (e.g., specific methods) afford limited scope.
Patent Validity and Obstacles:
Claims' novelty and inventive step are challenged during examination. Competing patents often scrutinize such claims within existing prior art, which may include earlier compounds or formulations disclosed in international patent filings or scientific publications.
Impact on Generic Entry:
Strong, broad claims, especially if covering core chemical entities, delay generic entry and patent challenges, prolonging market exclusivity.
Conclusion
TW201840317's scope primarily covers a novel pharmaceutical compound or formulation aimed at treating a specific medical condition. Its claims likely encompass both compound and method protections, contributing robustly to the Taiwanese drug patent landscape. The strategic positioning of this patent affects licensing opportunities, market exclusivity, and potential for enforcement against infringing generics.
A comprehensive understanding of its claims’ scope and their interaction with existing patents will be critical for stakeholders evaluating patent validity, freedom to operate, and licensing prospects.
Key Takeaways
-
Claim Breadth and Protection: The strength of TW201840317 hinges on the breadth of its independent claims. Broad claims covering core compounds extend exclusivity, while narrow claims may invite challenges.
-
Landscape Positioning: The patent adds to Taiwan's strategic patent pool for pharmaceutical innovations, especially in chemically complex or formulation-oriented patents aligned with regional R&D trends.
-
Licensing and Enforcement: Well-drafted claims influence the ability to license the patent widely and enforce against infringers, including generics.
-
Innovation Alignment: The patent reflects ongoing Taiwanese and international research focus areas, including novel drug entities and delivery methods, aligning with global patent strategies.
-
Monitoring Prior Art: Due to existing patents and scientific disclosures, continuous surveillance of prior art is essential to maintain the patent’s validity and value.
FAQs
1. What is the primary protection scope of TW201840317?
It primarily protects a specific chemical compound or formulation used for targeted therapeutic applications, including methods of synthesis or treatment.
2. How do the claims of TW201840317 influence its enforceability?
The enforceability depends on the breadth of the claims; broader claims provide stronger protection but face higher validity challenges, while narrow claims are easier to defend but limit scope.
3. Is TW201840317 part of a broader patent family?
Likely yes, as pharmaceutical companies typically file related patents internationally or regionally to extend protection and market reach.
4. How does TW201840317 compare with global patents?
It may share similarities with international patents covering similar compounds, but national filing specifics in Taiwan give it tailored enforceability in the region.
5. What are the implications for generic manufacturers?
If TW201840317 has broad, valid claims, it can delay patent expiry and subsequent generic entry, impacting market dynamics and pricing.
References
[1] Taiwanese Patent Act, Article 23.
[2] WIPO Patent Landscape Reports.
[3] European Patent Office (EPO) Guidelines on Patent Claims.
[4] Taiwan Intellectual Property Office Patent Search Database.
[5] Market reports on pharmaceutical patent trends in Asia.
